Fluoropyrimidine therapy in cancer patients was associated with a pooled cardiotoxicity incidence of 5.04% for all grades and 1.5% for grade 3 or higher.
Meta-Analysis (n=63,186)
Yes
What is the incidence and profile of fluoropyrimidine-associated cardiotoxicity in cancer patients?
Fluoropyrimidines are associated with a 5.04% overall incidence of cardiotoxicity, primarily cardiac ischemia and arrhythmia, with higher risks observed in esophageal cancer, continuous high-dose infusions, and combination therapies.
Aim: The cardiac toxicity that occurs during administration of anti-tumor agents has attracted increasing concern. Fluoropyrimidines have been used for more than half a century, but their cardiotoxicity has not been well clarified. In this study, we aimed to assess the incidence and profile of fluoropyrimidine-associated cardiotoxicity (FAC) comprehensively based on literature data. Methods: A systematic literature search was performed using PubMed, Embase, Medline, Web of Science, and Cochrane library databases and clinical trials on studies investigating FAC. The main outcome was a pooled incidence of FAC, and the secondary outcome was specific treatment-related cardiac AEs. Random or fixed effects modeling was used for pooled meta-analyses according to the heterogeneity assessment. PROSPERO registration number: (CRD42021282155). Results: A total of 211 studies involving 63,186 patients were included, covering 31 countries or regions in the world. The pooled incidence of FAC, by meta-analytic, was 5.04% for all grades and 1.5% for grade 3 or higher. A total of 0.29% of patients died due to severe cardiotoxicities. More than 38 cardiac AEs were identified, with cardiac ischemia (2.24%) and arrhythmia (1.85%) being the most frequent. We further performed the subgroup analyses and meta-regression to explore the source of heterogeneity, and compare the cardiotoxicity among different study-level characteristics, finding that the incidence of FAC varied significantly among different publication decades, country/regions, and genders. Patients with esophagus cancer had the highest risk of FAC (10.53%), while breast cancer patients had the lowest (3.66%). The treatment attribute, regimen, and dosage were significantly related to FAC. When compared with chemotherapeutic drugs or targeted agents, such a risk was remarkably increased (χ2 = 10.15, p < 0.01; χ2 = 10.77, p < 0.01). The continuous 5-FU infusion for 3–5 consecutive days with a high dosage produced the highest FAC incidence (7.3%) compared with other low-dose administration patterns. Conclusions: Our study provides comprehensive global data on the incidence and profile of FAC. Different cancer types and treatment appear to have varying cardiotoxicities. Combination therapy, high cumulative dose, addition of anthracyclines, and pre-existing heart disease potentially increase the risk of FAC.
Lu et al. (Thu,) conducted a meta-analysis in Cancer (n=63,186). Fluoropyrimidines was evaluated on Pooled incidence of fluoropyrimidine-associated cardiotoxicity (FAC). Fluoropyrimidine therapy in cancer patients was associated with a pooled cardiotoxicity incidence of 5.04% for all grades and 1.5% for grade 3 or higher.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: